China

BMI View: Multinational pharmaceutical companies will benefit more from China's national and provincial drug reimbursement lists (DRLs) as opposed to its national and provincial essential... 2012-02-21

BMI View: China continues to be the key emerging market for most multinational pharmaceutical companies and we continue to expect increasing investment into the country. Despite a potential... 2012-02-16

BMI View: Major domestic pharmaceutical companies will benefit from China's 12th five-year plan (FYP) for the pharmaceutical industry, as the government aims to improve the whole industry... 2012-02-07

In anticipation of an investment-led growth slowdown, BMI believes the Chinese government will increase its efforts to boost the country's social security net in order to control... 2012-02-03

BMI View: China's huge population of drug-naïve patients, coupled with the increasingly ageing population (and hence increasing burden from non-communicable diseases), will generate... 2011-12-06

BMI View: Potential approval of the first traditional Chinese medicine (TCM) by the US Food and Drug Administration (FDA) would be a huge landmark for the beleaguered TCM sector and... 2011-11-25

BMI View: China is the world's most attractive emerging pharmaceutical market. The key driver of growth is the government's commitment to providing affordable universal healthcare.... 2011-11-24

BMI View: Despite the upward revision to our Indian healthcare expenditure forecast, we continue to expect Chinese outperformance in the healthcare sector over the medium-to-long term,... 2011-11-14

BMI Core View: Emerging markets will drive industry growth. The importance of emerging markets to large multinational drugmakers cannot be overstated and BMI 's Pharmaceutical Expenditure... 2011-11-10

BMI View: Multinational pharmaceutical companies will increasingly look to China's second-tier cities as locations for their manufacturing plants, sales offices and, to a lesser extent,... 2011-10-24